US Pharma Firm Lilly para trial rokishe

Washington: October 14, 2020. Tuesday din, US pharmaceutical firm Eli Lilly para Covid-19  nemite  lab te antibody elaj kori thaka late-stage trial toh hosari kam nemite rokai thishe, koikena company para koishe. “Independent DSMB (data safety monitoring board) para fesla lowa toh Lilly para be manishe, keli koile, etu study kora samay patients khan kam kori thaka toh hosari nemite” koikena spokesperson para AFP logot statement te koishe. August moina para hospitalized Covid-19 patients logot control trial study Phase 3 toh soru hoikena ase, aro etu United States pithor te 50 chaka te loiase aro etu oper te Singapore aro Denmark para 10,000 manuh ke thaiboli bahana ase koishe. Etu kam toh Unites States National Institutes of Health para koriase. Monoclonal antibody alaj laga kotha besi olai thakishe. President Donald Trump ekte therapy lowa beche, etu biotech firm Regeneron paa bona ase, aro etu elaj para tai Covid-19 phal hoishe. Jaa hafta te, Lilly para Regeneron be tai khan ke emergency samay elaj koribo nemite US Food aro Drug Administration logot applied korishe. Etu kam roka para Lilly para dosura Covid-19 nemite clinical trials jai thaka toh dhuk hobona nai khobor thaka nai. Monoclonal antibodies toh notun tawai ase ke, etu tawai para cancer aro autoimmune disease nemite bhal ase koishe. Dosura kam bahl ekta te, kaun manuh khan bemar bhal koikena ase, tai khan laga antibodies toh etai bemari hoi thaka manuh khan logot te thikena larai koribo thibo ase. Etai Covid-19 alaj nemite rokina thaka toh, Lily para bemar thaka bhal kora manuh laga antibody toh lab te anikena kam kori ase koishe. Aro etu drop hesab te kam kori ase. Lilly para keman jun logot lakishe nohoile hosari laga kam toh eku khobor  kowa nai.